Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two stage, open-label, phase II trial assessing the efficacy of a single oral agent AZD4547 in malignant mesothelioma.

Next Previous
X
Search
Trial Profile

A two stage, open-label, phase II trial assessing the efficacy of a single oral agent AZD4547 in malignant mesothelioma.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 091 (Primary)
  • Indications Malignant-mesothelioma; Mesothelioma
  • Focus Therapeutic Use
  • Acronyms FRAME

    • Most Recent Events

    • 01 Aug 2021 Primary endpoint (To determine the progression free survival at 6 months using AZD4547 in patients with malignant pleural mesothelioma who have previously undergone first line chemotherapy. CT scan of the chest & abdomen will be used to assess disease progression.) has not been met, according to published in the Clinical and Experimental Ophthalmology.
    • 01 Aug 2021 Results assessing ocular adverse events and retinal changes during fibroblast growth factor receptor (FGFR) inhibitor (AZD4547) anticancer therapy, published in the Clinical and Experimental Ophthalmology.
    • 10 Sep 2019 Final results presented at the 20th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top